Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Maryland, Baltimore
With
National Institute of Mental Health (NIMH)
Age
18–64
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Any race
Subjects will meet DSM-IV criteria for schizophrenia or schizoaffective disorder
Judged clinically stable and will not exceed threshold levels of positive, depressive, and/or extrapyramidal symptoms
The minimum level of negative symptoms will be defined as follows:
* Scale for the Assessment of Negative Symptoms (SANS) total score (minus the global items, and inappropriate affect, poverty of content of speech and attentional items) 20 or greater; OR
* SANS alogia global item score 3 or greater
The maximum level of psychotic, depressive, and extrapyramidal symptoms at the beginning and end of leading in:
* Brief Psychiatric Rating Scale (BPRS) psychotic factor score (4-items) less or equal to 16
* BPRS Anxiety/Depression factor score (4-items) less than or equal to 14
* Simpson-Angus-Scale (SAS) total score (13-items) less than or equal to 10
Subjects will be required to be on the same antipsychotic(s) for two months and on the same dose for the last month
You may not be if
Participants with an organic brain disorder; mental retardation; or a medical condition, whose pathology or treatment could alter the presentation or treatment of schizophrenia or significantly increase the risk associated with the proposed treatment protocol
Participants with intermittent alcohol or substance use will not be excluded unless they have met DSM-IV criteria for alcohol or substance abuse (other than nicotine) within the last month.
Participants may be treated with one or more antipsychotics, except chlorpromazine, thioridazine, or mesoridazine. These latter antipsychotics are excluded because of the concern that their anticholinergic properties may interfere with the accurate assessment of galantamine efficacy.
Participants may not be treated with anticholinergic medications or have clinically significant extrapyramidal symptoms. Additionally, subjects treated with glycopyrrolate will be accepted.
Female participants may not be pregnant
Female subjects may not be taking olanzapine at doses higher than 30 mg . Male subjects may not be taking olanzapine at doses higher than 40 mg.
